Curcumin is the major phenolic diarylheptane derivative in Curcuma longa and has been reported to possess pharmacological activities. Unfortunately this compound suffers from poor bioavailability and rapid neutral-alkaline degradation. Co-crystal of curcumin is one option under exploration, motivated by the fact that a number of active pharmaceutical ingredient (API) co-crystals with improved dissolution have recently been synthesized. Hence, co-crystallization technique highlights an alternative means to improve the performance of curcumin.
Within our work evidences for a co-crystal was ascertained from DSC, Kofler hot stage screening and PXRD, and all confirmed a new crystal phase could have been formed between curcumin and a co-crystallizing agent, nicotinamide. We report that re-crystallization step essentially aids the purification of commercial curcumin, a herbal based actives. Otherwise the prevalence of a new crystal phase in solvent-mediated co-crystallization will be significantly reduced.
Besides, phase diagram is an effective tool for the study of solubility behaviours in co-crystal system. In order to acquire related techniques, fenbufen, a poorly water soluble drug, was selected. The result showed the huge difference in solubility between fenbufen and nicotinamide lead to difficulty in the construction of phase diagram.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/4253 |
| Date | January 2009 |
| Creators | Chan, Hin Chung Stephen |
| Contributors | Wright, Colin W. |
| Publisher | University of Bradford, The Institute of Pharmaceutical Innovation |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Thesis, research masters, MPhil |
| Rights | <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-nd/3.0/88x31.png" /></a><br />The University of Bradford theses are licenced under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Licence</a>. |
Page generated in 0.0029 seconds